U.S. Guidewires Market (2024 - 2030)

U.S. Guidewires Market Size & Trends

The U.S. guidewires market size was estimated at USD 791.2 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 4.9% from 2024 to 2030. Increasing prevalence of urological disorders, cardiovascular diseases, and Peripheral Artery Disease (PAD) is significantly driving the growth of the market. Moreover, growing number of minimally invasive surgeries paired with rising geriatric population is opportunistic for the product demand.

Factors such as rising number of coronary & peripheral intervention procedures and increase in geriatric population are resulting in high demand for minimally invasive surgeries in the country. This is expected to positively influence the market in the coming years. A majority of people in the U.S. are inclining towards noninvasive surgeries owing to the probability of high infection associated with invasive procedures.

Technological advancements, coupled with advanced product launches, to streamline the procedures and make them safer & more cost-effective, are among the key factors contributing to market growth. For instance, in June 2023, Teleflex Incorporated announced the launch of the Wattson Temporary Pacing Guidewire. This guidewire is exclusively developed for use in Transcatheter Aortic Valve Replacement (TAVR) and Balloon Aortic Valvuloplasty (BAV). This guidewire provides dual functionality, supporting delivery of valve, and ventricular bipolar pacing. It is purposed to improve procedural efficiencies and limit complications associated with conventional methods.

Market Characteristics & Concentration

The industry growth stage is low (CAGR <5%) and pace of the growth depicts an accelerating trend. The U.S. guidewires industry is fragmented, which is marked by the presence of large number of companies competing for the highest market share. The industry is in low growth stage and will continue its trajectory in the coming 5-6 years.

The introduction of technological advancements has revolutionized urology guidewires in terms of sufficient flexibility and lubricity to navigate a tortuous ureter and pass possible obstructions. The E-Z Glider, Quattro, PTFE-Coated, Bentson, and Amplatz urology guidewires by Olympus ensure the right combination of torque, lubricity, and visibility for optimum results by providing a variety of sizes, core materials, coatings, and tips. All these guidewires are designed to ensure smooth tracking, rapid access, and maximum maneuverability. Zebra urology guidewire by Boston Scientific has kink-resistant nitinol core and PTFE coating jacket for torqueability, and a platinum distal tip for visual feedback. Such developments are projected to provide lucrative growth opportunities for the industry players.

The U.S. guidewires industry is characterized by a moderate level of M&A and collaboration activities undertaken by key manufacturers. Numerous players operating in the country are collaborating with other relevant companies to strengthen their portfolio and expand their reach. For instance, in June 2023, Sensome announced a strategic collaboration with Asahi Intecc. As per the deal, Asahi was entrusted to develop the next-gen Clotild Smart Guidewire for acute ischemic stroke treatment.

The industry is influenced by stringent regulatory norms and quality protocols imposed by various organizations, including the FDA. Strict product approval regulations have a significant impact on the operational capabilities of companies in the industry. Manufacturers aligning to robust compliance measures and a track record of following regulatory standards gain visibility from MedTech sponsors. However, compliance with these stringent regulations requires extensive resources, which creates challenges and acts as a barrier for newer and smaller companies entering the industry.

Product Insights

The coronary guidewires segment dominated the market with a share of 43.1% in 2023. This dominance is attributable to high usage rates and increasing preference for minimally invasive coronary procedures. Increased public awareness regarding cardiovascular diseases and minimally invasive treatment options will likely lead to more people seeking these procedures, pushing up demand for coronary guidewires. Continuous technological advancements, and rising healthcare accessibility is anticipated to predict larger market share for coronary guidewire segment in the foreseeable future.

The neurovascular guidewires segment is projected to witness the fastest CAGR over the forecast period. This growth can be linked to an elevated risk of neurovascular conditions that impact the cerebellum, brain vascular system, and spinal cord. These conditions include aneurysms, arteriovenous malformations, cavernoma, cerebral haemorrhage, dural arteriovenous fistula, and stroke.

Key U.S. Guidewires Company Insights

Key companies in the industry include Abbott, Terumo Medical Corporation, B. Braun Melsungen AG, and Boston Scientific Corporation among others. Manufacturers in the sector are emphasizing on enhancing guidewire design, making them more trackable, flexible, and maneuverable. Such improvements enable better navigation and access to complex anatomical structures.

Recent Developments

• In November 2023, Xenter, based in the U.S has introduced a new type of guidewire for transcatheter aortic valve replacement (TAVR) procedures.

• In June 2023, Sensome has partnered with Asahi Intecc, to create a new, AI-powered smart guidewire for treating acute ischemic stroke.

• In May 2023, Artiria announced that it had received the FDA approval for its real-time, deflectable guidewire for the treatment of stroke and associated neurovascular and peripheral conditions.

• In August 2022, BD unveiled the launch of the first-ever human trial of a sirolimus-coated balloon. This development helped expand the range of available therapies for peripheral artery disease.

U.S. Guidewires Market